AinosAIMD
AIMD
About: Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
Employees: 44
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
60% more capital invested
Capital invested by funds: $34.5K [Q4 2024] → $55.3K (+$20.8K) [Q1 2025]
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
33% more funds holding
Funds holding: 9 [Q4 2024] → 12 (+3) [Q1 2025]
0.19% more ownership
Funds ownership: 0.54% [Q4 2024] → 0.73% (+0.19%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for AIMD.
Financial journalist opinion
Based on 4 articles about AIMD published over the past 30 days
Neutral
Accesswire
1 week ago
Water Tower Research Highlights Ainos' AI Nose Accuracy Breakthrough in Elderly Care Monitoring: SmellTech Gets Smarter
AI Nose accuracy in elderly care improved to 85% with additional Smell ID training AI-friendly healthcare policies to provide tailwinds for commercial rollout SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 3, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting a significant milestone in the Company's AI Nose project for elderly care. AI Nose has reached approximately 85% accuracy in excretion odor detection-improving over the recently met internal milestone of 80%.
Neutral
Accesswire
2 weeks ago
Ainos AI Nose Improves Accuracy in Hygiene Monitoring To 85% from 80%
Accelerating Toward Commercial Rollout as AI Nose Solves Critical Gaps in Elder Care SAN DIEGO, CA / ACCESS Newswire / May 29, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, announced today that its proprietary AI Nose platform achieved approximately 85% accuracy in detecting excretion odors data, an improvement from 80% previously, based on collected from 254 participant instances in Japan and Taiwan, resulting in 2119 valid entries for subsequent statistical evaluation. The milestone validates AI Nose as a deploy able solution for non-contact hygiene monitoring in long-term care (LTC) and positions Ainos to lead the emerging SmellTech category.
Neutral
Accesswire
3 weeks ago
Ainos Showcases Breakthrough AI Nose Technology at COMPUTEX 2025 with Japan's Robotics Partner
Robotic Smell Intelligence Goes Live at Asia's Premier AI Tech Stage SAN DIEGO, CA / ACCESS Newswire / May 22, 2025 / Ainos, Inc. (NASDAQ:AIMD)(Nasdaq:AIMDW) ("Ainos"), a pioneer in AI-driven scent digitization, announced the official debut of its proprietary AI Nose platform at COMPUTEX 2025, alongside ugo, Inc, Japan's top service robotics company. This milestone marks the first public demonstration of real-time robotic olfaction-a new sensory category poised to transform smart robotics, environmental AI, and safety infrastructure.
Neutral
Accesswire
3 weeks ago
Ainos Reports Breakthrough Interim Results in VELDONA Clinical Trial for FCGS, Signaling New Era in Companion Animal Immunotherapy
Early results show steroid-free remission, opening pathway into $13B global pet dental health market VELDONA delivers consistent anti-inflammatory effects, strengthening Ainos' positioning in companion animal immunotherapy SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 19, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a pioneer of low-dose oral interferon therapeutics, today announced compelling interim results from its ongoing veterinary clinical trial using low-dose interferon VELDONA for treating Feline Chronic Gingivostomatitis ("FCGS"), a chronic inflammatory conditions in cats. The interim results demonstrate meaningful improvements in inflammation and a consistent reduction in steroid dependency, indicating strong commercial and scientific potential for a novel class of immunotherapy in companion animals.
Neutral
Accesswire
1 month ago
Water Tower Research Highlights Ainos' Significant Commercial Traction and Strategic Milestones Across Multiple Sectors
412% revenue growth reflects AI Nose sales in elderly care Expanding AI-driven scent tech beyond healthcare into robotics and industrial applications SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 14, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting the Company's significant progress in commercializing its AI-driven scent digitization platform, AI Nose, and expanding into multiple market verticals. Notably, Ainos has achieved a key milestone of achieving over 80% accuracy in its senior care project.
Neutral
Accesswire
1 month ago
Ainos Reports First Quarter 2025 Financial Results
Q1 revenues increased 412% year over year, driven by AI Nose products Delivers strong turnaround from gross loss to gross profit in Q1 AI Nose gains traction beyond healthcare with strategic partnerships in robotics and semiconductor sectors VELDONA® program advances with TFDA and IRB Approvals for two clinical trials in Taiwan SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 12, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "Q1 2025 represents a significant step forward in advancing our long-term strategy to build a differentiated healthcare and technology company powered by scent digitization, AI-enhanced diagnostics and innovative therapeutics.
Neutral
Accesswire
1 month ago
Ainos Forms Partnership with ASE's Key Site to Power AI-Driven SmellTech in Semiconductor Smart Manufacturing
Expanding AI Nose's Commercial Opportunity for Smarter, Safer, and More Sustainable Factories SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 30, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-driven scent digitization, has announced it has formed a strategic partnership with ASE Chung Li ("ASECL") - a key site of Advanced Semiconductor Engineering, Inc., the world's leading provider of semiconductor assembly and test services. This new milestone expands the joint effort to power AI scent digitization in smart manufacturing.
Neutral
Accesswire
1 month ago
Water Tower Research Spotlights Ainos' Smell Integration in Humanoid Robot - AI Smelltech is Progressing Rapidly
Robotic smelltech by AI Nose moves from concept to integration in weeks Partnership fast-tracks robotic smell integration as global service robotics market nears $40.6B, Japan $1.2B SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 23, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting the Company's successful installation of its AI Nose technology onto a humanoid robot developed by ugo, Inc., Japan's leading service robot company. The milestone, achieved just weeks after announcing the partnership, demonstrates fast execution and marks a global first in robotic smell integration.
Neutral
Accesswire
1 month ago
Ainos and ugo Complete First Robotic Smell Integration in Japan
Milestone Ignites a New Era of Smell-Enabled Robotics Installs AI Nose in ugo Robot; Real-World Pilots to Begin in Weeks SAN DIEGO, CA / ACCESS Newswire / April 21, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, has successfully installed its proprietary AI Nose olfaction module on a humanoid robot developed by ugo, Inc. ("ugo"), Japan's top service robotics company. Completed on April 9, 2025, the installation marks the world's first robot with a functional sense of smell, a breakthrough that redefines the frontier of robotics, AI, and human-machine interaction.
Neutral
Accesswire
2 months ago
Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjögren's Syndrome in Taiwan
Dual Trials Accelerate VELDONA® Toward Rare Disease Market Entry Bridging Strategy Aims to Fast-Track U.S. Regulatory Approvals SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 14, 2025 / Ainos, Inc. (Nasdaq:AIMD, AIMDW) ("Ainos" or the "Company"), pioneer of low-dose oral interferon therapeutics, today announced significant progress in advancing its oral interferon drug platform, VELDONA® in the rare disease space. The Taiwan Food and Drug Administration (TFDA) has approved the Company's clinical trial for human immunodeficiency virus (HIV)-related oral warts, while Institutional Review Board (IRB) clearance has been granted for its upcoming Sjögren's Syndrome (pSS) study.
Charts implemented using Lightweight Charts™